ENZ Stock Overview
Enzo Biochem, Inc., an integrated diagnostics, clinical lab, and life sciences company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology.
Enzo Biochem Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$2.19|
|52 Week High||US$4.15|
|52 Week Low||US$1.98|
|1 Month Change||-12.40%|
|3 Month Change||2.34%|
|1 Year Change||-38.14%|
|3 Year Change||-36.71%|
|5 Year Change||-78.86%|
|Change since IPO||-20.48%|
Recent News & Updates
Enzo Biochem: Activist Pressure Could Finally Lead To A Company Sale
On June 9, Enzo Biochem announced a new strategic review that may finally lead to the sale of the long-mismanaged company. Since late 2021, positive changes have taken place - long-time CEO Rabbani was replaced with an independent CEO, an experienced activist was appointed to the Board and Rabbani-affiliated President resigned. For these reasons, a company or asset sale may eventually materialise. The set-up appears to exist because of low liquidity and analyst coverage. Downside is limited by undervaluation and net cash position of ENZ.
|ENZ||US Healthcare||US Market|
Return vs Industry: ENZ underperformed the US Healthcare industry which returned 7.9% over the past year.
Return vs Market: ENZ underperformed the US Market which returned -20.3% over the past year.
|ENZ Average Weekly Movement||9.4%|
|Healthcare Industry Average Movement||8.0%|
|Market Average Movement||6.9%|
|10% most volatile stocks in US Market||15.7%|
|10% least volatile stocks in US Market||2.8%|
Stable Share Price: ENZ is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: ENZ's weekly volatility (9%) has been stable over the past year.
About the Company
Enzo Biochem, Inc., an integrated diagnostics, clinical lab, and life sciences company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. It operates through three segments: Life Sciences Products, Clinical Laboratory Services, and Therapeutics. The Life Sciences Products segment develops, manufactures, and markets products and tools to clinical research, drug development, and bioscience research customers.
Enzo Biochem Fundamentals Summary
|ENZ fundamental statistics|
Is ENZ overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ENZ income statement (TTM)|
|Cost of Revenue||US$64.16m|
Last Reported Earnings
Apr 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.13|
|Net Profit Margin||-5.88%|
How did ENZ perform over the long term?See historical performance and comparison
Is ENZ undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 2/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for ENZ?
Other financial metrics that can be useful for relative valuation.
|What is ENZ's n/a Ratio?|
Price to Sales Ratio vs Peers
How does ENZ's PS Ratio compare to its peers?
|ENZ PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
INFU InfuSystem Holdings
CCM Concord Medical Services Holdings
OHCS Optimus Healthcare Services
ENZ Enzo Biochem
Price-To-Sales vs Peers: ENZ is good value based on its Price-To-Sales Ratio (1x) compared to the peer average (14x).
Price to Earnings Ratio vs Industry
How does ENZ's PE Ratio compare vs other companies in the US Healthcare Industry?
Price-To-Sales vs Industry: ENZ is good value based on its Price-To-Sales Ratio (1x) compared to the US Healthcare industry average (1.3x)
Price to Sales Ratio vs Fair Ratio
What is ENZ's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||1x|
|Fair PS Ratio||n/a|
Price-To-Sales vs Fair Ratio: Insufficient data to calculate ENZ's Price-To-Sales Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of ENZ when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate ENZ's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate ENZ's fair value for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
How is Enzo Biochem forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Enzo Biochem has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Discover growth companies
How has Enzo Biochem performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ENZ is currently unprofitable.
Growing Profit Margin: ENZ is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ENZ is unprofitable, and losses have increased over the past 5 years at a rate of 16.7% per year.
Accelerating Growth: Unable to compare ENZ's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ENZ is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (3.2%).
Return on Equity
High ROE: ENZ has a negative Return on Equity (-10.55%), as it is currently unprofitable.
Discover strong past performing companies
How is Enzo Biochem's financial position?
Financial Health Score3/6
Financial Health Score 3/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: ENZ's short term assets ($62.3M) exceed its short term liabilities ($24.7M).
Long Term Liabilities: ENZ's short term assets ($62.3M) exceed its long term liabilities ($17.0M).
Debt to Equity History and Analysis
Debt Level: ENZ has more cash than its total debt.
Reducing Debt: ENZ's debt to equity ratio has increased from 0.2% to 7% over the past 5 years.
Debt Coverage: ENZ's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: Insufficient data to determine if ENZ's interest payments on its debt are well covered by EBIT.
Discover healthy companies
What is Enzo Biochem current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
|Enzo Biochem Dividend Yield vs Market|
|Company (Enzo Biochem)||n/a|
|Market Bottom 25% (US)||1.7%|
|Market Top 25% (US)||4.7%|
|Industry Average (Healthcare)||1.4%|
|Analyst forecast in 3 Years (Enzo Biochem)||n/a|
Notable Dividend: Unable to evaluate ENZ's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ENZ's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ENZ's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ENZ's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as ENZ has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Hamid Erfanian (52 yo)
Mr. Hamid Erfanian serves as Chief Executive Officer at Enzo Biochem, Inc. since November 8, 2021 and serves as Director since January 03, 2022. He served as Member of Executive Board at EUROIMMUN Medizini...
Experienced Management: ENZ's management team is seasoned and experienced (5.5 years average tenure).
Experienced Board: ENZ's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: ENZ insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
|15 Jul 22||BuyUS$6,050||Kara Cannon||Individual||2,500||US$2.42|
|12 Jul 22||BuyUS$28,375||Bradley Radoff||Individual||12,500||US$2.27|
|05 Jul 22||BuyUS$264,000||Bradley Radoff||Individual||120,000||US$2.20|
|16 Jun 22||BuyUS$275,500||Bradley Radoff||Individual||125,000||US$2.21|
|15 Jun 22||BuyUS$10,074||Hamid Erfanian||Individual||4,600||US$2.19|
|14 Jun 22||BuyUS$7,525||David Bench||Individual||3,500||US$2.15|
|21 Mar 22||SellUS$30,200||Roumell Asset Management, LLC||Company||10,000||US$3.02|
|21 Dec 21||BuyUS$2,484,891||Bradley Radoff||Individual||683,000||US$3.64|
|21 Oct 21||BuyUS$1,492,463||Bradley Radoff||Individual||414,501||US$3.86|
|19 Oct 21||BuyUS$302,700||Radoff Family Foundation, Endowment Arm||Company||90,599||US$3.38|
|05 Oct 21||BuyUS$2,465,421||Bradley Radoff||Individual||720,599||US$3.50|
|01 Oct 21||BuyUS$752,752||Radoff Family Foundation, Endowment Arm||Company||219,401||US$3.50|
|Owner Type||Number of Shares||Ownership Percentage|
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
|Ownership||Name||Shares||Current Value||Change %||Portfolio %|
Enzo Biochem, Inc.'s employee growth, exchange listings and data sources
- Name: Enzo Biochem, Inc.
- Ticker: ENZ
- Exchange: NYSE
- Founded: 1976
- Industry: Health Care Services
- Sector: Healthcare
- Implied Market Cap: US$106.698m
- Shares outstanding: 48.72m
- Website: https://www.enzo.com
Number of Employees
- Enzo Biochem, Inc.
- 527 Madison Avenue
- New York
- New York
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|ENZ||NYSE (New York Stock Exchange)||Yes||Common Stock||US||USD||Jun 1980|
|EZB||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Jun 1980|
|0IHV||LSE (London Stock Exchange)||Yes||Common Stock||GB||USD||Jun 1980|
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/09/29 00:00|
|End of Day Share Price||2022/09/29 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.